Sino Biopharm announced a strategic partnership with Germany’s Boehringer Ingelheim to develop and commercialize Boehringer 's innovative oncology pipeline in mainland China. The agreement includes three clinical stage assets and an unspecified number of preclinical projects, all of them aimed at oncology targets. Sino Biopharm actively seeks in-licensing deals from other companies. Last year, it signed a commercialization deal with Shanghai’s Investisbio for a KRAS G12C inhibitor and another agreement for a portfolio of 12 innovative Pfizer drugs. More details....

Stock Symbol: (HK: 01177)

Share this with colleagues:  

D3 Bio, a Shanghai oncology biotech, closed a $62 million Series A+ financing round, a large amount for an early-stage company in the past few years. The funding will use the funds to ramp up development of D3 Bio's preclinical assets and a global clinical trial of D3S-001, a next-gen small molecule KRAS G12C inhibitor that the company believes has best-in-class potential. The A+ round was led by Medicxi, a European life sciences investment firm. In 2020, D3 Bio raised an impressive $200 million in a Series A round. More details....

Share this with colleagues:  

Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange. The company will use the proceeds to support its portfolio of three clinical stage rare disease endocrine therapies, including growth hormone deficiency. In 2018, Visen was formed by Ascendis Pharma A/S of Denmark to bring its therapies to China. Ascendis partnered the venture with an investor syndicate led by Vivo Capital and Sofinnova that contributed $40 million in capital for a 50% stake. In 2021, Visen closed a $150 million Series B financing led by Sequoia China. More details....

Share this with colleagues:  

Insilico Medicine, an AI drug discovery-development company based in Hong Kong and New York, has completed an initial filing for a Hong Kong IPO. Insilico has developed several platforms that use generative AI to analyze biology, chemistry and clinical trials for next-gen AI systems. Formed in 2014, Insilico develops products for its own portfolio and out-licenses other candidates, while retaining their intellectual property. Two years ago, the company bragged that it needed only 30 months to move its lead drug from discovery to clinical trials at a cost of $2.5 million. More details....

Share this with colleagues:  

ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors. The company’s three clinical stage assets target ovarian cancer and other FRα-expressing solid tumors. A privately owned company, ProfoundBio raised $112 million in a B Round financing earlier this year. ProfoundBio is led by CEO Baiteng Zhao, a former associate director at Seagen, a Seattle ADC company that was acquired by Pfizer for $43 billion in 2023. More details....

Share this with colleagues: